Results 11 to 20 of about 6,034 (173)

Loss of SOCS1 in Donor T Cells Exacerbates Intestinal GVHD by Driving a Chemokine-Dependent Pro-Inflammatory Immune Microenvironment. [PDF]

Adv Sci (Weinh)
T cell‐specific Socs1 knockout leads to inflammatory differentiation of CD8+ T cells, prompting the STAT1/2 complex to drive the activation of Ccl5, Ccr5, and Cxcr3, and promoting the skewing of monocytes toward a pro‐inflammatory M1 macrophage lineage.
Wu Z, Wang B, Jiang X, Zhang F, Huang Q, Wu X, Fan S, Zhang Q, Zhou J, Tang J, Mo XD, Wang Y, Chang YJ, Guo H, Huang XJ.   +14 more
europepmc   +2 more sources

Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model

Molecules, 2021
Rheumatoid arthritis (RA) is a chronic inflammatory disease mainly affecting the synovial joints. A highly potent antagonist of C-C chemokine receptor 5 (CCR5), maraviroc (MVC), plays an essential role in treating several infectious diseases but has not ...
Mushtaq A. Ansari, Ahmed Nadeem, Saleh A. Bakheet, Sabry M. Attia, Mudassar Shahid, Faris S. Alyousef, Mohammed A. Alswailem, Mohammed Alqinyah, Sheikh F. Ahmad   +8 more
doaj   +1 more source

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.

PLoS ONE, 2019
Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days.
M Ghannad, M Dennehy, C la Porte, I Seguin, D Tardiff, R Mallick, E Sabri, G Zhang, S Kanji, D W Cameron   +9 more
doaj   +1 more source

Immune non-response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches. [PDF]

HIV Med
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Silvestre C, Gross A, Makinson A.
europepmc   +2 more sources

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

PLoS ONE, 2018
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind trial,
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby   +11 more
doaj   +1 more source

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

Journal of Virus Eradication, 2015
Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich, Nicolas Chomont, James L.K. Fletcher, Suteeraporn Pinyakorn, Alexandra Schuetz, Irini Sereti, Rungsun Rerknimitr, Robin Dewar, Eugene Kroon, Claire Vandergeeten, Rapee Trichavaroj, Nitiya Chomchey, Thep Chalermchai, Nelson L. Michael, Jerome H. Kim, Praphan Phanuphak, Nittaya Phanuphak   +16 more
doaj   +1 more source

Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in rats.

PLoS ONE, 2013
Maraviroc is a CC-chemokine receptor 5 (CCR5) antagonist with potent antiviral and cancer preventive effects. Recent evidence suggests that the co-existence of CCR5 in various cell types is involved in inflammation.
Fu-Chao Liu, Yung-Fong Tsai, Huang-Ping Yu   +2 more
doaj   +1 more source

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. [PDF]

PLoS ONE, 2015
Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 ...
Benoit Visseaux, Charlotte Charpentier, Gilles Collin, Mélanie Bertine, Gilles Peytavin, Florence Damond, Sophie Matheron, Eric Lefebvre, Françoise Brun-Vézinet, Diane Descamps, ANRS CO5 HIV-2 Cohort   +10 more
doaj   +1 more source

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

PLoS ONE, 2014
BackgroundThe effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown.MethodsSubjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc ...
Ai Kawana-Tachikawa, Josep M Llibre, Isabel Bravo, Roser Escrig, Beatriz Mothe, Jordi Puig, Maria C Puertas, Javier Martinez-Picado, Julia Blanco, Christian Manzardo, Jose M Miro, Aikichi Iwamoto, Anton L Pozniak, Jose M Gatell, Bonaventura Clotet, Christian Brander, MARAVIBOOST Investigators   +16 more
doaj   +1 more source

Clinical Utility of Maraviroc

Clinical Drug Investigation, 2011
Maraviroc belongs to the family of chemokine (C-C motif) receptor 5 (CCR5) antagonists that prevent the entry of human immunodeficiency virus (HIV) into host CD4+ T cells by blocking the CCR5 co-receptor R5. Maraviroc is currently the only CC5R co-receptor inhibitor that has been approved for clinical use in HIV-1-infected patients carrying the CCR5 ...
Parra, Jorge, Portilla, Joaquin, Pulido, Federico, Sanchez-de la Rosa, Rainel, Alonso-Villaverde, Carlos, Berenguer, Juan, Blanco, Jose L., Domingo, Pere, Dronda, Fernando, Galera, Carlos, Gutierrez, Felix, Kindelan, Jose M., Knobel, Hernando, Leal, Manuel, Lopez-Aldeguer, Jose, Marino, Ana, Miralles, Celia, Molto, Jose, Ortega, Enrique, Oteo, Jose A.   +19 more
  +8 more sources